Corticosteroids for Multiple Sclerosis: I. Application for Treating Exacerbations

Neurotherapeutics

Volumn 4, Issue 4, 2007, Pages 618-626

  Frohman, Elliot M ^a   Shah, Anjali ^a   Eggenberger, Eric ^b   Metz, Luanne ^c   Zivadinov, Robert ^d   Stüve, Olaf ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b East Lansing   (United States)

^c CALGARY HEALTH REGION   (Canada)

^d UNIVERSITY AT BUFFALO   (United States)

^e VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

ACTH; Corticosteroids; pulse steroids

Indexed keywords

CARBAMAZEPINE; CORTICOSTEROID; CORTICOTROPIN; DEXAMETHASONE; METHYLPREDNISOLONE; PHENYTOIN; PREDNISONE; WARFARIN;

ANXIETY DISORDER; ARTICLE; AVASCULAR NECROSIS; CATARACT; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; EDEMA; GASTRITIS; GLAUCOMA; HUMAN; HYPERTENSION; IN VITRO STUDY; LYMPHOID ORGAN; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; SKIN DISEASE; SLEEP DISORDER; WEAKNESS;

ADRENAL CORTEX HORMONES; HUMANS; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES;

EID: 34848825438     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2007.07.008     Document Type: Article

References (53)

1. Uhthoff W. Untersuchungen über die bei der multiplen Herdsklerose vorkommenden Augenstorungen. [In German]. Arch Psychiatr Nervenkrankh 20 (1889) 55
2. Hansen B.S., Hussain R.Z., Lovett-Racke A.E., Thomas J.A., and Racke M.K. Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity. J Neuroimmunol 172 (2006) 94-103
3. Goodin D., Frohman E.M., Garmany Jr. G.P., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58 (2002) 169-178 [Erratum in: Neurology 2002;59:480]
4. Dalakas M.C. Current treatment of the inflammatory myopathies. Curr Opin Rheumatol 6 (1994) 595-601
5. Kirwan J.R., and The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 333 (1995) 142-146
6. Hall S., and Conn D.L. Immunosuppressive therapy for vasculitis. Curr Opin Rheumatol 7 (1995) 25-29
7. Guillevin L., and Lhote F. Distinguishing polyarteritis nodosa from microscopic polyangiitis and implications for treatment. Curr Opin Rheumatol 7 (1995) 20-24
8. Youssef P.P., Haynes D.R., Triantafillou S., et al. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum 40 (1997) 1400-1408
9. Droogan A.G., Crockard A.D., McMillan S.A., and Hawkins S.A. Effects of intravenous methylprednisolone therapy on leukocyte and soluble adhesion molecule expression in MS. Neurology 50 (1998) 224-229
10. Filipovic S.R., Drulovic J., Stojsavljevic N., and Levic Z. The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis. J Neurol Sci 152 (1997) 147-153
11. Patzold T., Schwengelbeck M., Ossege L.M., Malin J.P., and Sindern E. Changes of the MS Functional Composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis. Acta Neurol Scand 105 (2002) 164-168
12. Humm A.M., Z'Graggen W.J., Buhler R., Magistris M.R., and Rosler K.M. Quantification of central motor conduction deficits in multiple sclerosis patients before and after treatment of acute exacerbation by methylprednisolone. J Neurol Neurosurg Psychiatry 77 (2006) 345-350
13. Buttgereit F., Wehling M., and Burmester G.R. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum 41 (1998) 761-767
14. Gold R., Buttgereit F., and Toyka K.V. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 117 (2001) 1-8
15. Wehling M. Specific, nongenomic actions of steroid hormones. Annu Rev Physiol 59 (1997) 365-393
16. Boumpas D.T., Chrousos G.P., Wilder R.L., Cupps T.R., and Balow J.E. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 119 (1993) 1198-1208
17. Adcock I.M., Caramori G., and Ito K. New insights into the molecular mechanisms of corticosteroids actions. Curr Drug Targets 7 (2006) 649-660
18. Falkenstein E., Norman A.W., and Wehling M. Mannheim classification of nongenomically initiated (rapid) steroid action(s). J Clin Endocrinol Metab 85 (2000) 2072-2075
19. Buttgereit F., Brand M.D., and Burmester G.R. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol 58 (1999) 363-368
20. Yong V.W., Power C., Forsyth P., and Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2 (2001) 502-511
21. Rosenberg G.A., Dencoff J.E., Correa Jr. N., Reiners M., and Ford C.C. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46 (1996) 1626-1632
22. Orchinik M., Murray T.F., and Moore F.L. A corticosteroid receptor in neuronal membranes. Science 252 (1991) 1848-1851
23. Gametchu B. Glucocorticoid receptor-like antigen in lymphoma cell membranes: correlation to cell lysis. Science 236 (1987) 456-461
24. Gametchu B., Watson C.S., and Wu S. Use of receptor antibodies to demonstrate membrane glucocorticoid receptor in cells from human leukemic patients. FASEB J 7 (1993) 1283-1292
25. Diba F., Watson C.S., and Gametchu B. 5′UTR sequences of the glucocorticoid receptor 1A transcript encode a peptide associated with translational regulation of the glucocorticoid receptor. J Cell Biochem 81 (2001) 149-161
26. Chaudhari B.R., Murphy R.F., and Agrawal D.K. Following the TRAIL to apoptosis. Immunol Res 35 (2006) 249-262
27. Navratil J.S., Liu C.C., and Ahearn J.M. Apoptosis and autoimmunity. Immunol Res 36 (2006) 3-12
28. + ions into concanavalin A-stimulated thymocytes. Biochem J 326 (1997) 329-332
29. Schmidt J., Gold R., Schonrock L., Zettl U.K., Hartung H.P., and Toyka K.V. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 123 (2000) 1431-1441
30. Zamvil S.S., and Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 8 (1990) 579-621
31. Levine S., Wenk E.J., Muldoon T.N., and Cohen S.G. Enhancement of experimental allergic encephalomyelitis by adrenalectomy. Proc Soc Exp Biol Med 111 (1962) 383-385
32. McCombe P.A., Nickson I., Tabi Z., and Pender M.P. Corticosteroid treatment of experimental autoimmune encephalomyelitis in the Lewis rat results in loss of V beta 8.2+ and myelin basic protein-reactive cells from the spinal cord, with increased total T-cell apoptosis but reduced apoptosis of V beta 8.2+ cells. J Neuroimmunol 70 (1996) 93-101
33. Pender M.P., Nguyen K.B., McCombe P.A., and Kerr J.F. Apoptosis in the nervous system in experimental allergic encephalomyelitis. J Neurol Sci 104 (1991) 81-87
34. Durelli L., Cocito D., Riccio A., et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 36 (1986) 238-243
35. Beck R.W., Cleary P.A., Anderson M.M., et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326 (1992) 581-588
36. Sellebjerg F., Frederiksen J.L., Nielsen P.M., and Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 51 (1998) 529-534
37. Brusaferri F., and Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 247 (2000) 435-442
38. Rose A.S., Kuzma J.W., Kurtzke J.F., Namerow N.S., Sibley W.A., and Tourtellotte W.W. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs. placebo-final report. Neurology 20 (1970) 1-59
39. Humm A.M., Z'Graggen W.J., Buhler R., Magistris M.R., and Rosler K.M. Quantification of central motor conduction deficits in multiple sclerosis patients before and after treatment of acute exacerbation by methylprednisolone. J Neurol Neurosurg Psychiatry 77 (2006) 345-350
40. Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, Candelise L. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis.
41. Ciucci G., Midgard R., and Candelise L. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 4 (2000) CD001331
42. Hoogervorst E.L., Polman C.H., and Barkhof F. Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Mult Scler 8 (2002) 415-419
43. Herishanu Y.O., Badarna S., Sarov B., Abarbanel J.M., Segal S., and Bearman J.E. A possible harmful late effect of methylprednisolone therapy on a time cluster of optic neuritis. Acta Neurol Scand 80 (1989) 569-574
44. Stüve O., Marra C.M., Jerome K., et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59 (2006) 743-747
45. Stüve O., Marra C.M., Jerome K., et al. Altered CD4:CD8 T cells ratios in cerebrospinal fluid of natalizumab-treated multiple sclerosis patients. Arch Neurol 63 (2006) 1383-1387
46. Stüve O., Marra C.M., Petra C.D., et al. The potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 64 (2007) 169-176
47. Sellebjerg F., Schaldemose Nielsen H., Fredericksen J.L., and Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 52 (1999) 1479-1484
48. Alam S.M., Kyriakides T., Lawden M., and Newman P.K. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 56 (1993) 1219-1220
49. Barnes D., Hughes R.A.C., Morris R.W., et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349 (1997) 902-906
50. Metz L.M., Sabuda D., Hilsden R.J., Enns R., and Meddings J.B. Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis. Neurology 53 (1999) 2093-2096
51. Morrow S.A., Stoian C.A., Dmitrovic J., Chan S.C., and Metz L.M. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 63 (2004) 1079-1080
52. Lackner T.E. Interaction of dexamethasone with phenytoin. Pharmacotherapy 11 (1991) 344-347
53. Pradat P., Robert-Gnansia E., Di Tanna G.L., Rosano A., Lisi A., Mastroiacovo P., and Contributors to the MADRE database. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Terato 67 (2003) 968-970